Performance of an individualized, subcutaneous, basal-bolus insulin regimen for the management of prednisolone-associated hyperglycemia in hospitalized patients: a proof-of-concept study
Authors' conclusion
Individualizing a subcutaneous BBI regimen for management of prednisolone-associated hyperglycemia was associated with a modest reduction in mean POC glucose, an increased proportion of blood glucose measurements within the target range, and reduced short-term glycemic variability.
Study context
- Population
- Adult inpatients with prednisolone-associated hyperglycemia
- Participants
- 23 vs 24
- Exposure
- Individualized subcutaneous basal-bolus insulin (BBI) (dose from 24-hour IV insulin infusion) vs standard weight-based subcutaneous BBI
- Individualized BBIn = 23
- Standard weight-based BBIn = 24reference
- Outcome
- Mean 24-hour point-of-care (POC) glucose concentration
- Follow-up
- Day 1
Methodological detailsproof-of-concept, historical controls
- Proof-of-concept
- Historical controls
Main finding
As reported in the abstract
Mean POC glucose
P = 0.07
Observational data: associations, not effects.
Further findings
Proportion of glucose measurements within target range (exploratory) · day 1 · higher with Individualized BBI
P = 0.0007
| Outcome | Individualized BBI | Standard weight-based BBI | P value |
|---|---|---|---|
| SD of glucose (exploratory) · day 1Lower with Individualized BBI | 3.1 ± 1.5 | 4.0 ± 1.6 | P = 0.04 |
Glucose SD, mean glucose and stress hyperglycemia ratio (SHR) over 2 days
- Increase in glucose SD in both groups
- No significant difference in mean glucose and SHR between groups
Original publication
Performance of an individualized, subcutaneous, basal-bolus insulin regimen for the management of prednisolone-associated hyperglycemia in hospitalized patients: a proof-of-concept study. BMJ Open Diabetes Res Care. Published 9 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →